SLCTR/2008/008招募中未知
Efficacy of low dose Rituximab with methotrexate compared to leflunomide with methotrexate in patients with refractory rheumatoid arthritis: A randomized double blind controlled clinical trial
A Bour & Company (Ltd)0 个研究点目标入组 40 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.18-65 years of age
- •2. must fulfill the revised 1987 American Rheumatism association criteria for at least 6 months
- •3.Swollen joint count ³4 (28 joint count) and tender joint count ³4(28 joint count at screening and baseline
- •4.CRP ³6 mg/L OR ESR ³28 mm/h at screening
- •5. Patients who used methotrexate at 15-25 mg/wk for at least 12 weeks without response. This will include patients who failed to respond to additional treatment with either or both SSZ, chloroquine. patients who have used leflunomide will not be included
- •6.The doses of MTX must be stable for 4 weeks prior to baseline
- •7.Prednisolone <10 mg/day or equivalent glucocorticoids are permitted if dose stable for 4 weeks prior to baseline
- •8.Patients will be allowed to receive non-steroidal anti-inflammatory drugs if dose stable for ³4weeks prior to baseline
- •9.A negative serum pregnancy test at screening for female subjects of childbearing potential. Use of contraception in patients of reproductive potential
排除标准
- •History of or current inflammatory joint disease other than RA or other systemic rheumatic disorder
- •Patients with functional class IV according to ACR classification of functional status
- •Known hypersensitivity to any component of the tetanus toxoid adsorbed vaccine
- •Evidence of significant uncontrolled concomitant disease, such as diseases of heart, liver, lung, nervous system, renal, endocrine, or gastrointestinal disorders
- •Known active bacterial, viral, fungal, mycobacterial, or other infection or any major episode of infection requiring hospitalization or treatment with IV antibiotics within 4 weeks of Day 1 or oral antibiotics within 2 weeks of Day 1
- •History of serious recurrent or chronic infection history of deep space/tissue infection within 52 weeks prior to baseline. History of or currently active primary or secondary immunodeficiency, including HIV infection
- •History of cancer, including solid tumors and hematological malignancies
- •History of alcohol, drug, or chemical abuse within the 6 months prior to screening
- •Diagnosis of juvenile idiopathic arthritis/juvenile rheumatoid arthritis before age 16
- •Immunization with a live vaccine within 4 weeks prior to randomization (Day 1)
- •Serum creatinine > 1.4 mg/dl for women or > 1.6 mg/dl for men
- •AST or ALT > 2.5 times upper limit of normal
- •Platelet count < 100,000/ml
- •Hemoglobin < 8.0 g/dl
- •Neutrophils < 1.5x10^3/ml
- •Positive tests for hepatitis B surface antigen
- •Levels of IgG < 5.0 mg/ml and/or IgM = 0.4 mg/ml
研究者
相似试验
招募中
不适用
High-dose methotrexate with rituximab in patients with primary central nervous system lymphomaprimary central nervous system lymphomaJPRN-UMIN000012602Department of Neurosurgery, Institute of Health Biosciences,The University of Tokushima Graduate School30
尚未招募
不适用
Combination of rituximab and methotrexate followed by rituximab and cytarabine in elderly patients with primary CNS lymphomaKCT0003146Samsung Medical Center35
进行中（未招募）
1 期
The efficacy of treatment of patients with multiple sclerosis, a chronic, inflammatory, autoimmune, disease that leads to neurologic deficits and aggravates with flairs, with low doses of rituximab, an antibody directed against the CD20 epitope on B Lymphocytes, specific cells of the immune system contributing to the progression of the disease - a pilot trialRelapse Remitting Multiple SclerosisMedDRA version: 20.1Level: PTClassification code 10028245Term: Multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.0Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2017-000426-35-ATMedical University of Vienna - Department of Neurology70
进行中（未招募）
不适用
Efficacy of Rituximab treatment in patients with rheumatoid arthritis having inadequate response to TNF blockerTo investigate the efficacy of treatment with Rituximab (MabThera®) in patients with active RA whose current treatment with one or more TNF-blocker (Etanercept - Enbrel®, Infliximab – Remicade® or Adalimumab - Humira®) alone or in combination with MTX is insufficient measured by DAS28 activity index.EUCTR2006-004673-98-HURoche (Hungary) Ltd.20
尚未招募
4 期
Comparison of the effectiveness of two medicines namely Methotrexate and Apremilast in patients with a skin disease called psoriasisCTRI/2019/04/018854Yenepoya Medical College